Full text
2/2020
vol. 36
Case report
Psychotic disorders as an adverse effect of levetiracetam or discontinuation of mood stabilising drugs
- Institute of Psychiatry and Neurology in Warsaw
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 155–163
Data publikacji online: 2021/12/06
Article file
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: APA; 2013.
- Birger M, Swartz M, Cohen D, Alesh Y, Grishpan C, Kotelr M. Aggression: the testosterone-serotonin link. Israel Medical Association Journal. 2003; 5: 653–58.
- Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017; 76: 24–31.
- Chen Z, Lusicic A, O’Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain. 2016; 139: 2668–78.
- Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry. 2014; 14: 75.
- Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 2012; 38: 920–926.
- Cramer JA, De Rue K, Devinsky O. A Systematic Review of the Behavioral Effects of Levetiracetam in Adults With Epilepsy, Cognitive Disorders, or an Anxiety Disorder During Clinical Trials. Epilepsy Behav. 2003; 4: 124-32.
- de Almeida RM, Ferrari PF, Parmigiani S, Miczek KA. Esca lated aggressive behavior: dopamine, serotonin and GABA. European Journal of Pharmacology. 2005; 526: 51–64.
- Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampa nel. Behav Neurol. 2018; 2018: 2064027.
- Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochemical Pharmacology. 2003; 66: 179–89.
- Josephson CB, Engbers JDT, Jette N, Patten SB, Singh S, Sajobi TT, et al. Prediction tools for psychiatric adverse effects after levetiracetam prescription; Epilepsy Behav. 2019; 76: 49–55.
- Kang BS, Moon HJ, Kim YS, Lee KTS, Jung KH, Chu K, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disord 2013; 15: 302–10.
- Köksal A, Dirican AC, Altunkaynak Y, Yildirim EA. First Manic Episode Due to Discontinuation of Valproic Acid in a Patient With Epilepsy. The Journal of Neuropsychiatry and Clinical Neurosciences. 2014; 26: E60–E61.
- Lopez LM, Wassef AA, Molloy MS, Williams NG. Valproic Acid Induces Manifestations of Simultaneous Dopamine Enhancement and Reduction in Schizophrenia. Neuropsy chopharmacology. 2004; 29: 1217.
- Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et.al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences. 2004; 101: 9861–66.
- Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003; 61:704–06.
- Pinckaers F, Boon ME & Majoie MHJM. Risk factors pre disposing to psychotic symptoms during levetiracetam therapy: A retrospective study. Epilepsy & Behavior. 2019; 100: 106344.
- Sills GJ, Rogawski MA. Mechanisms of Action of Currently Used Antiseizure Drugs. Neuropharmacology. 2020; 168: 107966.
- Sirsi D & Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf. 2007; 6: 241–50.
- Wassef A, Baker J, Kochan LD. GABA and Schizophrenia: A Review of Basic Science and Clinical Studies. Journal of Clinical Psychopharmacology. 2003; 23: 601–640.
- Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychia tric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007; 10: 105–10.
